ADVAIR DISKUS combines fluticasone propionate and salmeterol in a dry-powder inhaler. The Diskus device and the prescribed strength matter: asthma and COPD do not share every labeled presentation, and this is not a rescue inhaler.
The approved uses and formulations described here follow US prescribing information. They may differ in other countries.
| Medicine detail | Details |
|---|---|
| Active ingredient(s) | fluticasone propionate / salmeterol (as salmeterol xinafoate) |
| Medicine class | Inhaled corticosteroid / long-acting beta2 agonist (ICS/LABA) |
| Forms and strengths | Diskus dry-powder inhaler: 100/50, 250/50 and 500/50 mcg per inhalation; Advair HFA excluded |
Keep Diskus separate from HFA
This reference covers the Diskus dry-powder device, with 100/50, 250/50 and 500/50 mcg presentations. Advair HFA is a different inhaler product with separate instructions. Fluticasone reduces inflammation and salmeterol is a long-acting bronchodilator; the two-ingredient identity must stay clear on the medicine list.
Source: [1]
Asthma and COPD labeling differ
The US label includes asthma from age 4 and maintenance treatment of airflow obstruction and reduction of exacerbations in COPD. Younger children's asthma and COPD have specific strength restrictions. The COPD-labeled Diskus strength is 250/50; do not assume that every Diskus presentation is interchangeable for every indication.
Source: [1]
Maintenance use and inhaler technique
The label describes twice-daily administration and explicitly excludes relief of acute bronchospasm. Use the supplied device instructions and ask for a technique check. Rinse the mouth with water after use without swallowing to reduce oral-thrush risk. A worsening breathing pattern requires review of the action plan, not extra maintenance inhalations.
Source: [1]
Allergy and other important precautions
Severe milk-protein allergy is a contraindication because the powder contains lactose with milk proteins. Oral candidiasis and pneumonia in people with COPD are important risks. Corticosteroid-related effects can include adrenal, bone, growth and eye problems. Sudden worsening of breathing after inhalation needs immediate assessment.
Source: [1]
Avoid overlapping long-acting bronchodilators
The label advises against another LABA-containing medicine because of overdose risk. Some strong CYP3A4 inhibitors also require review. Check every inhaler by ingredient and device, not just brand color. If an access guide discusses Diskus, HFA or generics together, confirm that its product context matches the exact prescription.
The ADVAIR DISKUS and SYMBICORT comparison brings the two product identities and selected label facts together for further reading.
Source: [1]
Questions and answers
Does this page cover Advair HFA?
No. It is scoped to the Diskus dry-powder product; HFA has a different device and prescribing information.
Can ADVAIR DISKUS replace a rescue inhaler?
No. The US label excludes relief of acute bronchospasm. Follow the clinician's separate rescue plan.
Is lactose intolerance the same as the label's milk-protein restriction?
No. The contraindication concerns severe milk-protein allergy. A clinician should assess the person's actual allergy history.
Related reading
Sources
Sources checked 27 October 2026. This information does not replace advice from your healthcare professional. For complete warnings and instructions, read the product information and consult the prescribing team.
Reviewed by: Mattias Hagman, PhD
About the reviewer:
Dr Mattias Hagman (PhD, University of Sydney) has an academic background and experience working with healthcare-related content and regulated industries. He has lecturing experience at international universities, including Stockholm University and the University of Malta.
Last reviewed: October 2026